Nicardipine
Cardene, Nicardipine (nicardipine) is a small molecule pharmaceutical. Nicardipine was first approved as Cardene on 1988-12-21. It is used to treat hypertension, stable angina, and variant angina pectoris in the USA. It is known to target potassium voltage-gated channel subfamily A member 4 and adenosine receptor A3.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| cardiovascular diseases | D002318 |
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
Cardene, Nicardipine (discontinued: Cardene, Nicardipine)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Nicardipine hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER | Chiesi Farmaceutici | N-019734 RX | 2008-07-31 | 1 products, RLD, RS |
| CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER | Chiesi Farmaceutici | N-019734 RX | 2008-07-31 | 1 products, RLD, RS |
| CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER | Chiesi Farmaceutici | N-019734 RX | 2008-11-07 | 1 products, RLD, RS |
| NICARDIPINE HYDROCHLORIDE | Hikma Pharmaceuticals | N-022276 RX | 2008-07-24 | 1 products, RLD, RS |
| NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE | Hikma Pharmaceuticals | N-022276 RX | 2016-04-07 | 2 products, RLD, RS |
Show 5 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| cardene | New Drug Application | 2016-08-06 |
| cardene iv | New Drug Application | 2025-02-21 |
| nicardipine hydrochloride | ANDA | 2025-09-19 |
| nicardipine hydrochloride in sodium chloride | ANDA | 2025-06-30 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| hypertension | EFO_0000537 | D006973 | I10 |
| stable angina | — | D060050 | I20.89 |
| variant angina pectoris | — | D000788 | I20.1 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE, SENORES PHARMS | |||
| 2024-03-20 | CGT | ||
HCPCS
No data
Clinical
Clinical Trials
59 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | 1 | 1 | 5 | 3 | 6 | 16 |
| Ischemic stroke | D000083242 | — | — | — | — | 2 | 1 | 1 | 4 |
| Covid-19 | D000086382 | — | U07.1 | — | — | — | 1 | 2 | 3 |
| Intracranial vasospasm | D020301 | EFO_1000994 | G45.9 | — | 1 | — | 1 | 1 | 3 |
| Coronary artery disease | D003324 | — | I25.1 | 1 | — | — | 1 | 1 | 3 |
| Emergencies | D004630 | — | — | — | — | — | 2 | 1 | 3 |
| Hypertensive crisis | D000096003 | — | I16 | — | — | — | 2 | 1 | 3 |
| Hypotension | D007022 | EFO_0005251 | I95 | — | — | — | 2 | 1 | 3 |
| Coronavirus infections | D018352 | EFO_0007224 | B34.2 | — | — | — | 1 | 1 | 2 |
| Angle class iii malocclusion | D008313 | — | M26.213 | — | — | — | 1 | — | 1 |
Show 5 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hemorrhage | D006470 | MP_0001914 | R58 | 1 | 1 | 1 | — | 7 | 10 |
| Cerebral hemorrhage | D002543 | — | — | 1 | — | 1 | — | 5 | 7 |
| Pre-eclampsia | D011225 | EFO_0000668 | O14 | — | — | 2 | — | 1 | 3 |
| Heart failure | D006333 | EFO_0003144 | I50 | — | — | 1 | — | 1 | 2 |
| Muscle cramp | D009120 | — | — | — | — | 1 | — | — | 1 |
| Spasm | D013035 | — | M62.83 | — | — | 1 | — | — | 1 |
| Vasodilation | D014664 | — | — | — | — | 1 | — | — | 1 |
| Eclampsia | D004461 | — | O15 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Stroke | D020521 | EFO_0000712 | I63.9 | 1 | 1 | — | — | 4 | 6 |
| Subarachnoid hemorrhage | D013345 | EFO_0000713 | I60 | — | 2 | — | — | 3 | 5 |
| Thrombectomy | D017131 | — | — | — | 1 | — | — | — | 1 |
| Aneurysm | D000783 | — | I72.9 | — | 1 | — | — | — | 1 |
| Thoracic aortic aneurysm | D017545 | EFO_0004282 | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pain | D010146 | EFO_0003843 | R52 | 1 | — | — | — | 1 | 2 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | 1 | — | — | — | — | 1 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | 1 | — | — | — | — | 1 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 1 | — | — | — | — | 1 |
| Coronary disease | D003327 | — | — | 1 | — | — | — | — | 1 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | 1 | — | — | — | — | 1 |
| Burns | D002056 | — | T30.0 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Intracranial hemorrhages | D020300 | EFO_0000551 | I62 | — | — | — | — | 2 | 2 |
| Hypoxia | D000860 | — | R09.02 | — | — | — | — | 2 | 2 |
| Infections | D007239 | EFO_0000544 | — | — | — | — | — | 1 | 1 |
| Menorrhagia | D008595 | EFO_0003945 | N92.0 | — | — | — | — | 1 | 1 |
| Hemophilia a | D006467 | EFO_0007267 | D66 | — | — | — | — | 1 | 1 |
| Down syndrome | D004314 | EFO_0001064 | Q90 | — | — | — | — | 1 | 1 |
| Pneumonia | D011014 | EFO_0003106 | J18 | — | — | — | — | 1 | 1 |
| Blood coagulation disorders | D001778 | EFO_0009314 | D68.9 | — | — | — | — | 1 | 1 |
| Mucocutaneous lymph node syndrome | D009080 | EFO_0004246 | M30.3 | — | — | — | — | 1 | 1 |
| Hyperaldosteronism | D006929 | — | E26 | — | — | — | — | 1 | 1 |
Show 30 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Nicardipine |
| INN | nicardipine |
| Description | Nicardipine is a racemate comprising equimolar amounts of (R)- and (S)-nicardipine. It is a calcium channel blocker which is used to treat hypertension. It has a role as an antihypertensive agent, a calcium channel blocker, a vasodilator agent and an autophagy inhibitor. It contains a (S)-nicardipine and a (R)-nicardipine. |
| Classification | Small molecule |
| Drug class | phenylpyridine vasodilators; tricyclic compounds |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)Cc2ccccc2)C1c1cccc([N+](=O)[O-])c1 |
Identifiers
| PDB | — |
| CAS-ID | 55985-32-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1484 |
| ChEBI ID | 7550 |
| PubChem CID | 4474 |
| DrugBank | DB00622 |
| UNII ID | CZ5312222S (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Nicardipine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 6,523 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,254 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use